A six-gene model (favorable LMO2, BCL6, FN1; unfavorable CCND2, SCYA3, BCL2) was reported to identify approximately one third of DLBCL patients whose 5-year survivals were less than 27 % [21]. Here, BCL2 is linked to diffuse large B-cell lymphoma.